Autologous transplant of hematopoietic stem cell (HSCs) corrected by ex vivo gene transfer has been investigated as an alternative therapeutic approach to allogeneic bone marrow transplantation (BMT) for primary immunodeficiencies. Long-term immune reconstitution has been achieved in gene therapy (GT) trials for severe combined immunodeficiency (SCID) caused by IL-2 receptor g [1] [2] [3] or adenosine deaminase (ADA) deficiency. [4] [5] [6] In patients with ADA-SCID, transplant of retrovirally transduced CD34 1 cells after low-intensity conditioning has resulted in longterm engraftment of multilineage HSCs 7 with correction of metabolic and immunologic defects. 4, 8 After BMT or in lymphopenic conditions (ie, resulting from genetic or acquired immunodeficiencies or infections), the T-cell compartment can be sustained by (1) homeostatic proliferation of pre-existing T-cell clones, [9] [10] [11] (2) de novo thymopoiesis, or (3) extrathymic differentiation. 12 After BMT, the reconstitution of the peripheral T cells is mainly driven by memory cells, particularly at early follow-up, in both pediatric and adult recipients. [13] [14] [15] There is limited information on the relative contribution of the different T-cell subsets and the various mechanisms of differentiation during the T-cell pool reconstitution after GT treatment.
Despite evidence of very long-term engraftment, senescence of the newly reconstituted hematopoietic cells as a result of the replicative demand imposed on donor HSCs and mature cells has been proposed as a potential threat to the successful outcome of BMT. [16] [17] [18] Because autologous stem/progenitor cells are expanded short-term ex vivo with cytokines before reinfusion, 5 GT may result in an increased senescence of the reconstituting cells.
To investigate the dynamic of T-cell reconstitution after GT, we performed a detailed analysis focused on the cell cycle and senescence status of the different cell subsets, referring to a group of pediatric patients undergoing allogeneic BMT and healthy children as controls. Our results reveal that homeostatic proliferation represents a substantial mechanism of T-cell repopulation in early phases after GT, like allogeneic BMT, resulting in telomere shortening and T-cell receptor excision circle (TREC) content dilution in the naive T-cell pool compared with pediatric controls. However, we did not find evidence of senescence in the progenitor cell compartment after treatment.
Our data give new insight of the role of homeostatic expansion after GT and confirm this treatment as a valid alternative to BMT for ADA-SCID and possibly for other genetic immunodeficiencies.
METHODS Samples
The research has been conducted on biological specimens from patients with ADA-SCID treated with GT, pediatric patients who underwent BMT, and healthy pediatric and adult subjects. The ADA-SCID HSC-GT clinical trials were approved by the San Raffaele Scientific Institute and National Authorities and registered at ClinicalTrials.gov (nos. NCT00598481 and NCT00599781). Seven patients with ADA-SCID have been described previously 4 ; the other 5 displayed typical early onset and were enrolled after failure or unavailability of long-term polyethylene glycol-ADA and were treated between 0.5 and 6.2 years of age (A. Aiuti, unpublished data). Patients received a single infusion of autologous CD34
1 cells transduced with GIADAl vector after busulfan infusion (4 mg/kg intravenously). None of the patients received polyethylene glycol-ADA after GT. Peripheral blood (PB) and BM samples from patients with ADA-SCID, patients undergoing BMT, or healthy donors, and umbilical cord blood were collected and used on informed consent for research purposes in agreement with the rules defined by the San Raffaele Hospital (Milan, Italy) and Bambino Ges u Pediatric Hospital (Rome, Italy) Ethical Committees. Permission from healthy donors' or patients' parents/guardians was obtained. The age range of pediatric and adult healthy controls was 1 to 5 years and 20 to 60 years, respectively. The pediatric BMT group was composed of 16 patients with different diagnoses pretransplant (see this article's Table E1 in the Online Repository at www.jacionline.org). All patients underwent BMT from an HLA-identical donor. Ten patients underwent myeloablative conditioning before transplant, 19, 20 2 received reduced intensity regimens, and 4 patients with SCID were not conditioned. At the moment of the analysis, none of them was experiencing graft-versus-host disease (GVHD) except 1 (chronic GVHD limited to the oral cavity). We divided both GT and BMT groups into early (<2 years) and late (>2 years) follow-up (Table E1) to distinguish between early and late phases of immune reconstitution.
Proliferation and cell cycle analysis
Blood samples were stained with antibodies anti-CD4 or CD8 phycoerythrin-Cy7, CD62L-phycoerythrin, CD45RA-PerCp-Cy5.5, and CD45RO-APC (all from Becton Dickinson, San Diego, Calif, except the anti-CD45RA-PerCpCy5.5, obtained from Biolegend, San Diego, Calif). After red blood cell lysis, cell cycle analysis was performed by combining Ki67 intracellular staining 21, 22 and the DNA-specific dye Vybrant Violet (Invitrogen, Carlsbad, Calif). Details about the staining can be found in this article's Methods in the Online Repository at www.jacionline.org. Samples were analyzed with a BD-LSR II Flow Cytometer (Becton Dickinson).
T-cell immunophenotypic analysis
PBMCs were stained with the following antibodies (all from Becton Dickinson): CD3-PerCp, T-cell receptor (TCR)-gd-fluorescein isothiocyanate (FITC), CD56-APC, CD8a-PE-Cy7, CD4-PE or CD3-PerCp, TCR-gd-FITC, CD56-APC, CD8a-PE-Cy7, and CD8b-PE. For the identification of the CD8aa subset, we referred to the gating strategy described by Konno et al. 23 
Telomere length quantification
Telomere length quantification was performed by the quantitative polymerase chain reaction (qPCR) approach based on a previously established method, 24 TREC content analysis and quantification of vectortransduced cells DNA extracted from naive and memory T cells was tested for the quantification of recent thymic emigrants by qPCR, using specific primers for TREC amplification, as described. 25 Quantification of vector containing cells was performed as described. 5 All qPCRs were run in a 7900 Fast Real Time PCR System (Applied Biosystems, Carlsbad, Calif).
Statistical analysis
For statistical data analysis, we applied a 2-tailed Mann-Whitney test considering the data set significantly different according to a P < .05: *P < .05; **P < .005; ***P < .001.
In all the graphs, median values are shown. In the box and whiskers representation, median and interquartile range are shown. Data were analyzed with the Graph-Pad Prism program, version 4.02 (Graph Pad Software, La Jolla, Calif).
RESULTS

Contribution of different T-cell subsets to immune reconstitution after GT
We measured the proportion of naive, central memory, effector memory, and T effector memory CD45RA 1 (TEMRA) 26 
cells in both CD4
1 and CD8 1 PB T-cell subsets in GT-treated patients, using as controls adult or pediatric healthy donors and pediatric patients undergoing allogeneic HLA-identical BMT (see this article's Fig E1 in the Online Repository at www.jacionline.org; Table E1 ). We found that phenotypically naive (CD45RO -CD45RA 1
CD62L
1 ) CD4 1 and CD8 1 cells were present at both early (<2 years) and late (>2 years) follow-up after GT and were significantly reduced compared with age-matched controls, but in the range of adult healthy donors (Fig 1) . In the early phase after treatment, GT patients displayed a higher proportion of naive CD4 1 and CD8 1 cells compared with BMT patients, whereas no significant differences were observed at later time points. The main circulating CD4 Among less represented T-cell subsets, we found no differences among the distribution of CD8aa, CD8a 
CD3
1 cells, described as increased in elderly subjects, 27 was increased 2-fold in the GT group compared with pediatric controls and BMT patients (Fig 2, B) . Moreover, a significant increase in the percentage of CD3 1 TCR-gd cells was detected in the GT group, both in the CD4 -
CD8
- (Fig 2, C) and in the CD3 1 CD56 1 (activated) cell subsets (Fig 2, D) .
Cell cycling in naive and memory T cells is increased in the early phase after GT
We performed a cell cycle analysis in both the CD4 1 and CD8 1 compartments by measuring the percentage of cells expressing the G1 phase marker Ki67 (Fig E1) . At early follow-up, a significantly higher proportion of cycling cells was observed in CD4 1 -cell-naive and central memory cell subsets from both GT and BMT groups compared with controls (Fig 3, A and B) , and a tendency was observed also in CD8 1 -naive and central memory cells (Fig 3, E and F) . Naive cycling cells decreased in frequency at later time points in both GT and BMT groups (Fig 3, A and E; see this article's Fig E4 in the Online Repository at www. jacionline.org), although not all patients reached the controls' levels. In the CD4
1 effector memory compartment, we observed a similar pattern at early and late time points, whereas cycling cells CD8
1 effector memory and TEMRA cell subsets were more dispersed (Fig 3, C, D 
, G, H).
We did not observe any statistically significant difference in the percentage and in the absolute number of cycling cells between the GT and the BMT groups (see this article's Table E2 in the Online Repository at www.jacionline.org). Our data indicate that the increased cell cycling in the naive compartment at early time points and its persistence at low but detectable levels represent an important mechanism to sustain homeostasis of the peripheral blood T-cell compartment after GT. Analysis of the S/G2/M phases across the different study groups and the different cellular populations did not show any significant difference, as shown in this article's Fig E5 in the Online Repository at www. jacionline.org.
Next, we measured TREC content by qPCR in sorted naive T cells. The number of TRECs was significantly lower in GT and BMT patients compared with healthy pediatric patients, in agreement with the increased cellular turnover of the naive compartment (Fig 4) .
Telomere length after GT is shortened in naive T cells but not in the BM compartment and granulocytes As shown in Fig 5, A, no difference in the median telomere length of BM MNC from the GT and BMT groups was observed with respect to healthy controls. Moreover, CD15
1 myeloid cells isolated from the PB and BM, which should reflect changes at the level of progenitor cells, showed similar telomere length in both treated and control groups (Fig 5, B and C) . As expected on the basis of the different age of the subjects, pediatric and adult granulocytes displayed shorter telomeres than those derived from umbilical cord blood cells (Fig 5, C) .
T cells from GT patients showed a reduced telomere length than pediatric controls, in the range of BMT-treated patients and adult controls (Fig 5, D) . Because this could reflect a different proportion of naive and memory cells within the samples, we measured telomere length in sorted naive CD3 
CD45RO
1 T cells (Fig 6) . As expected, naive cells displayed longer telomeres than memory cells in all groups, and naive T cells obtained from healthy pediatric subjects showed longer telomeres compared with adult-derived cells. However, telomere length in naive T cells from BMT and GT patients was significantly shortened compared with naive cells isolated from pediatric controls, showing a length similar to that in adult controls.
DISCUSSION
The goal of the current work was to deepen our knowledge of the in vivo dynamics of hematopoietic cells during immune reconstitution after autologous transplant of gene-corrected CD34 1 cells. Our data show that the recovery of the peripheral T-cell compartment after HSC GT for ADA-SCID is driven by both naive and memory cells, to an extent comparable to what is observed in our age-matched cohort of patients undergoing allogeneic BMT and in previous reports in pediatric and adult BMT recipients. [13] [14] [15] Our cohort of pediatric BMT patients was heterogeneous and included only a minority of patients with ADA-SCID. Nevertheless, we did not find statistically significant differences within this cohort by comparing the absolute number of lymphocytes or T-cell subsets counts with respect to conditioning or diagnosis (data not shown; Fig E2) . After GT, immune reconstitution occurs at a slower pace compared with that of the control BMT group 4, 28 (see also Fig E2) . This is in part expected because GT patients received an infusion of purified CD34 1 cells, whereas in our control group the HLA-identical graft was T-cell-replete. Indeed, in the early phase posttransplant, the percentage of naive CD4 and CD8 cells was higher after GT than BMT, whereas CD4 and CD8 effector memory cells were more represented in BMT patients than GT patients. Nevertheless, memory cells were also overrepresented in GT patients, similar to what was observed during early immune reconstitution in children undergoing allogeneic transplant of purified CD34
1 cells. 14 Because we can exclude that mature T cells have been cotransplanted with the ex vivo cultured CD34 1 cells, the most likely explanation for the presence of phenotypically memory T cells is the survival of pre-existing, nontransduced circulating T cells, which were generated on enzyme replacement therapy. 4 Indeed, at early followup, a substantial proportion of the circulating naive and memory T cells was nontransduced (Fig E3) . Gene-corrected cells became the majority over time because of the selective advantage for ADA 1 T cells, possibly occurring during peripheral expansion and/or antigen-specific stimulation. J ALLERGY CLIN IMMUNOL VOLUME 127, NUMBER 6 Although the immune phenotype analysis was affected by a large intragroup variability, the relative distributions of memory cells were closer to the pattern observed in the adult rather than pediatric healthy controls for both the GT and BMT groups.
Human gd T cells represent a heterogeneous population of non-MHC-restricted cells involved in the early response to pathogens, 29 in the lymphoid stress-surveillance response, sharing characteristics with the adaptive and innate immune responses, 30 particularly important early in life. 31 Because patients with ADA-SCID show alterations in thymic function and architecture, 32 the increase in gd T cells observed in the GT group could be related to the slow recovery of the thymic activity, implying a disadvantage in the ab TCR rearrangement. Moreover, the expression of CD8aa, a marker associated with extrathymic differentiation, 33, 34 was not different across the considered study groups, indicating that after GT, like BMT, the immune reconstitution process is mainly thymus derived.
The combined cell cycle and immune phenotypic analysis revealed a higher percentage of cycling cells in the naive T-cell compartment from both the GT and BMT groups at early follow-up and a tendency to normalize at later time points. This suggests homeostatic proliferation as the substantial mechanism of T-cell repopulation in early phases after treatment, as described during lymphopenia. 35 Other investigators have proposed that the rapid proliferation observed after BMT is mainly associated with the occurrence of GVDH and infection. 36 In this regard, it is important to note that most GT patients did not experience infectious complications, and the GVHD-related bias is unlikely to occur because of the autologous nature of the transplant. Importantly, our molecular studies on vector integration 7, 37, 38 (and data not shown) and TCR-Vb repertoire analyses 4 confirmed that the presence of a cycling population was not associated with clonal expansion.
Although the safety of GT has been widely studied in terms of genotoxicity, 4, 7 other relevant biological questions remain open. In particular, aging of the newly differentiating progeny has been suggested as a potential side effect after BMT, even if this point is still debated. 18, 39, 40 In this regard, it has been hypothesized that cell senescence may be associated with the rapid expansion of engrafting HSCs aimed to repopulate the BM niches emptied by the conditioning regimen. Because during the gene transfer protocol procedures HSCs are manipulated in vitro and exposed to cytokines, this may increase the risk of premature senescence seen after standard BMT. According to our data, BM MNCs as well as BM and PB granulocytes of GT and BMTtreated patients did not show altered telomere length dynamics.
These data indicate that the gene transfer procedure does not induce cellular senescence of the progenitor compartment and are in agreement with the reported transient activation of the enzyme telomerase during in vitro stimulation of hematopoietic stem/ progenitor cells. 41 Indeed, preliminary experiments did not show shortening of telomeres after in vitro cytokine stimulation of CD34 1 cells (data not shown). On the contrary, both BMT and GT patients' T cells showed shorter telomeres than pediatric controls, in the range of healthy adult donors. Thus, T-cell senescence, as reported by other studies after BMT, 16, 17 cannot be ascribed simply to the skewing of memory T cells after transplantation but also is a result of a specific reduction in the naive compartment, in accordance with their increased proliferation after treatment. Along the same lines is the observed reduction in TREC content in naive T cells with respect to normal pediatric donors as a consequence of cell proliferation and consequently TREC dilution. Naive CD4 1 T cells are able to proliferate postthymically while retaining their naive FIG 5 . Telomere length analysis in the BM and PB compartments. The number of samples composing the different data sets is reported above the whiskers. In C, in the GT subset, 2 patients were included twice because they were analyzed at both early and late follow-up. BM MNC, Bone marrow mononuclear cells; NDa, adult normal donors; NDp, pediatric normal donors; PB, peripheral blood; UCB, umbilical cord blood.
phenotype and functional characteristics, balancing by peripheral self-renewal the reduced output from the thymus in lymphopenic condition and aging. 10, [42] [43] [44] Our observation also supports the need for combining different markers (ie, TREC content and Ki67 expression) for a correct thymic output evaluation in human beings, as recently suggested by different authors. 45, 46 In summary, our data show that T-cell reconstitution after GT for ADA-SCID, like allogeneic BMT, is driven by de novo thymopoiesis, as well as by homeostatic expansion of naive and memory T cells, especially in the first months after treatment. The latter mechanism could explain the telomere shortening observed in T cells from both GT and BMT-treated patients, whereas normal telomere length in the myeloid and BM compartment indicates no difference between the autologous and allogeneic procedure at the stem/progenitor cell level.
Overall, the current study provides novel findings on the kinetic and different T-cell subset contribution to immune reconstitution after GT in patients with SCID and confirms GT as a valid alternative to BMT. 
METHODS Proliferation and cell cycle analysis
Blood samples (100 mL) were stained with the antibodies anti-CD4 or CD8 phycoerythrin-Cy7, CD62L-phycoerythrin, CD45RA-PerCp-Cy5.5, and CD45RO-APC (all from Becton Dickinson, San Diego, Calif, except the anti-CD45RA-PerCp-Cy5.5 which was from Biolegend, San Diego, Calif), 15 minutes at room temperature. After red blood cell lysis, cells were washed, fixed with Cytofix/Cytoperm solution, and permeabilized with Perm/Wash solution (both from Becton Dickinson, used according to the manufacturer's instructions). Cells in the G1 phase were identified by Ki67 staining, performed using anti Ki67-FITC or IgG 1k -FITC (catalog no. 556026 by Becton Dickinson) 25 minutes at room temperature. Before washing, samples were incubated for an additional 5 minutes with Vybrant Violet (Invitrogen, Carlsbad, Calif) diluted 1:100. Samples were then washed and analyzed with a BD-LSR II Flow Cytometer (Becton Dickinson).
Telomere length quantification
Telomere length quantification was performed by the qPCR approach, using 36B4 as the normalizing gene.
Primers were as follows: Tel1b:5'-CGGTTTGTTTGGGTTTGGGTT TGGGTTTGGGTTTGGGTT-3'; Tel2b:5'-GGCTTGCCTTACCCTTACCC TTACCCTTACCCTTACCCT-3'; 36B4d:5'-CCCATTCTATCATCAACGGG TACAA-3'; 36B4u:5'-CAGCAAGTGGGAAGGTGTAATCC-3'. The composition of the reaction mix was as follows: genomic DNA (15 ng), 12.5 mL SybrGreen 2x mastermix (ABI Applied Biosystems Inc, Foster City, Calif), primers: Tel1b 100 nmol/L and Tel2b 900 nmol/L (or 36B4d 500 nmol/L and 36B4u 300 nmol/L), water to 25 mL.
Thermal profiles were as follows: In the GT group, 1 patient has been considered at both early and late follow-up. No statistically significant difference can be detected between the study groups. NDped, n 5 11; BMT group, n 5 13; GT group, n 5 13. 
